## Cabotegravir

**Status –** Access to Investigational Cabotegravir for ***treatment*** of HIV-1 infection in adult, who should be virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, is **AVAILABLE outside of Argentina, Australia, Austria, Belgium, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom and the United States.**

**Status -** Access to Investigational Cabotegravir for ***treatment*** of HIV-1 infection in adolescents age 12 and over weighing at least 35kg, who should be virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, is **AVAILABLE outside of Australia, Canada, Chile, Hong Kong, Japan, South Korea, Taiwan, Uganda, and United States**

**Status –** Access to Investigational Cabotegravir for HIV ***prevention*** is **AVAILABLE outside Africa, Australia, Austria, Belgium, Botswana, Brazil, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania Malawi, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United States and Zimbabwe.**

## Fostemsavir

**Status –** Access to investigational fostemsavir (600 mg extended-release tablets) for the treatment of HIV-1 infection for use in combination with other antiretroviral therapies in heavily treatment experienced adults is **AVAILABLE outside of Australia, Belgium, Canada, France, Germany, Greece, Italy, Luxembourg, Spain, United Kingdom and the United States.**

Refer to ClinicalTrials.gov identifier NCT04233047

## Dolutegravir Dispersible Tablets

**Status –** Access to Investigational Dolutegravir Dispersible Tablet formulation is **AVAILABLE Outside of the following countries:**

| | | | |
|---|---|---|---|
| **Angola** | **Denmark** | **Kenya** | **Slovenia** |
| **Austria** | **Dominican Republic** | **Lesotho** | **South Sudan** |
| **Belgium** | **Eswatini** | **Liberia** | **Spain** |
| **Benin** | **Ethiopia** | **Malawi** | **Sweden** |
| **Botswana** | **Finland** | **Mali** | **Switzerland** |
| **Burundi** | **France** | **Mauritius** | **Tanzania** |
| **Cambodia** | **Gambia** | **Mozambique** | **Uganda** |
| **Cameroon** | **Germany** | **Namibia** | **United Kingdom** |
| **Canada** | **Greece** | **Netherlands** | **United States** |
| **Chad** | **Guyana** | **Nigeria** | **Venezuela** |
| **Congo** | **Haiti** | **Norway** | **Zambia** |
| **Congo (Democratic Republic of)** | **Hungary** | **Papua New Guinea** | **Zimbabwe** |
| **Cote D'Ivoire** | **India** | **Poland** | |
| **Croatia** | **Ireland** | **Serbia** | |
| **Czech Republic** | **Israel** | **Slovakia** | |

Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least four weeks and weighing at least 3kg.

## Triumeq paediatric Dispersible Tablets

**Status –** Access to Investigational Triumeq paediatric Dispersable Tablet(s) is **AVAILABLE outside of the United States.**